Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?

Area of Science:

• Pediatric Oncology
• Cancer Genetics
• Molecular Diagnostics

Background:

• Neuroblastoma (NB) exhibits diverse clinical behaviors, from spontaneous regression to aggressive progression.
• Stage 4s NB and localized NB without bone/marrow involvement often have good prognoses, but limited biological data exists for untreated cases.
• Understanding genetic drivers of benign NB courses is crucial for targeted therapies.

Purpose of the Study:

• To identify specific genetic alterations associated with favorable clinical outcomes in neuroblastoma.
• To compare genetic profiles of localized and stage 4s NB with those of aggressive tumors.

Main Methods:

• Analysis of 54 localized and stage 4s neuroblastoma tumors using in situ hybridization, classical cytogenetics, Southern blotting, and PCR.
• Focus on genetic abnormalities including 1p36 deletions and MYCN oncogene amplifications.
• Comparison of genetic data between tumors with benign and aggressive clinical courses.

Main Results:

• Absence of 1p36 deletions and MYCN amplifications was observed in localized tumors with favorable outcomes.
• Near-triploidy was noted in localized tumors associated with a benign course.
• Aggressive tumors frequently exhibited genetic aberrations, particularly 1p36 deletions.

Conclusions:

• Intact 1p36, absence of MYCN amplification, and near-triploidy appear to be prerequisites for spontaneous regression and maturation in localized neuroblastoma.
• These genetic markers may aid in predicting neuroblastoma behavior and guiding treatment strategies.